1. Home
  2. TAOP vs GTBP Comparison

TAOP vs GTBP Comparison

Compare TAOP & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TAOP

Taoping Inc.

HOLD

Current Price

$2.33

Market Cap

2.9M

Sector

Technology

ML Signal

HOLD

Logo GT Biopharma Inc.

GTBP

GT Biopharma Inc.

HOLD

Current Price

$0.68

Market Cap

2.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TAOP
GTBP
Founded
1993
1965
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
2.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TAOP
GTBP
Price
$2.33
$0.68
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.1M
1.5M
Earning Date
12-08-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$36,196,786.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.81
$0.54
52 Week High
$24.75
$4.10

Technical Indicators

Market Signals
Indicator
TAOP
GTBP
Relative Strength Index (RSI) 50.62 47.14
Support Level $2.03 $0.58
Resistance Level $2.84 $0.82
Average True Range (ATR) 0.31 0.07
MACD 0.05 -0.01
Stochastic Oscillator 43.41 33.00

Price Performance

Historical Comparison
TAOP
GTBP

About TAOP Taoping Inc.

Taoping Inc is a provider of cloud-app technologies for smart city IoT platforms, digital advertising delivery, and other internet-based information distribution systems in China. Its operating segment includes Cloud-based Technology (CBT), Blockchain Technology (BT), and Traditional Information Technology (TIT). It generates maximum revenue from the CBT segment. CBT segment includes cloud-based products and services offered to customers in the private sector including new media, healthcare, education, and residential community management.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: